The COVID-19 pandemic has led to an urgent need for effective treatments of this unknown disease. As of January 2023, there have been over 620 million confirmed cases of the virus and more than six-and-a-half million deaths worldwide. In the UK alone, the numbers are staggering with more than 24 million cases and nearly 200,000 deaths during this time.
Various treatments have been developed and used to help people who have been hospitalised due to COVID-19 or are at high risk of needing hospitalisation. These include casirivimab/imdevimab, tocilizumab, remdesivir, baricitinib, and baricitinib with remdesivir for hospitalised patients. For patients at high risk, treatments include casirivimab/imdevimab, molnupiravir, nirmatrelvir/ritonavir, remdesivir, sotrovimab, and tixagevimab/cilgavimab.
The objective of this study was to summarise the current knowledge related to the clinical efficacy of these interventions and to conduct an economic evaluation that estimates the cost-effectiveness of each intervention against standard of care (SoC).
Despite the urgency, these treatments have not received positive guidance from the National Institute of Health and Care Excellence (NICE) before being routinely used. As the pandemic subsides, there is more need for a formal evaluation of these treatments.
The results of the study, however, should be treated with caution due to changes in the conditions when the pivotal studies were undertaken and the current conditions in terms of the SoC, the percentage of people who have been vaccinated and a change in the dominant SARS-CoV-2 variant.
🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?
Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.
#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs
🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?
The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.
Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.
#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess
🔍 Are you up-to-date with the latest advancements in HPV testing for head and neck cancer?
Our comprehensive article looks into the innovation of diagnostic methods for HPV status determination in head and neck squamous cell carcinoma (HNSCC). From traditional p16 immunohistochemistry to innovative liquid biopsies, discover the critical role these advancements play in prognosis, treatment planning, and improving patient outcomes.
Look into this essential topic and see how these insights could revolutionize clinical practices.
#SyenzaNews #oncology #HealthTech #HealthcareInnovation
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
